Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: A randomized, double-blind placebo-controlled study
Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: A randomized, double-blind placebo-controlled study
复制标题
DOI：
10.1016/j.jad.2010.04.008
复制
发表时间：
2010-10-01
影响因子：
6.6
通讯作者：
de Jonge, P.
中科院分区：
文献类型：
--
作者：
Bot, M.;Pouwer, F.;de Jonge, P.
背景：抑郁症在糖尿病患者中很常见。本研究是第一个测试omega-3乙基二十碳五烯酸(E-EPA)作为抗抑郁药物辅助治疗成人糖尿病抑郁症疗效的随机对照试验。方法：在VU大学医学中心，我们对25名符合DSM-IV标准的糖尿病患者进行了为期12周的E-EPA(1g/d)与安慰剂的平行干预研究，这些患者已经在使用抗抑郁药物。主要结果是抑郁症状的严重程度，通过蒙哥马利·阿斯伯格抑郁评定量表(MADRS)在基线和12周的随访中进行评估，每两周一次。在基线和12周的随访中采集血样，以测定红细胞膜中的EPA水平。结果：13名参与者被随机分配到E-EPA组；12名参与者被给予安慰剂。在12周的随访中，接受E-EPA的患者红细胞膜中的EPA水平增加了两倍，而接受安慰剂的参与者没有发现任何变化。随着时间的推移，两组患者的抑郁症状均显著减少(F=21.14，p
Background: Depression is common in individuals with diabetes. The present study is the first randomized controlled trial to test the efficacy of omega-3 ethyl-eicosapentaenoic acid (E-EPA) as adjuvant to antidepressant medication in the treatment of depression in adults with diabetes mellitus.Methods: In the VU University Medical Center, we conducted a 12-week, placebo-controlled, double-blind, parallel-group intervention study of E-EPA (1 g/day) versus placebo in 25 diabetes patients meeting DSM-IV criteria for major depressive disorder, who were already using antidepressant medication. The primary outcome was severity of depressive symptoms, assessed by the Montgomery Asberg Depression Rating Scale (MADRS) at baseline and 12-week follow-up at two-weekly intervals. Blood samples were collected at baseline and at 12-week follow-up to determine EPA levels in erythrocyte membranes. Data were analyzed with ANOVA for repeated measures.Results: Thirteen participants were randomly assigned to E-EPA; 12 participants were given placebo. At 12-week follow-up, erythrocyte membranes from patients receiving E-EPA contained tripled levels of EPA, while no changes were noted in participants receiving placebo. In both groups, depressive symptoms significantly decreased over time (F=21.14, p